Evidence map›Paper›PMID 28686681›Full record

ArticlePloS one2017

KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.

Roberto Littera, Gianbenedetto Piredda, Davide Argiolas, Sara Lai, Elena Congeddu, Paola Ragatzu, Maurizio Melis, Elisabetta Carta, Maria Benigna Michittu, Donatella Valentini and 14 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Frontiers in immunology · 2024
    Article
  8. Review
  9. MHC Class I Ligands of Rhesus Macaque Killer Cell Ig-like Receptors.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Liquid Biopsy, a Potential New Detection Method in Heart Allograft Rejection.Methods in molecular biology (Clifton, N.J.) · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Roberto LitteraRegional Transplant Center, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Gianbenedetto PireddaKidney Transplant Unit, Department of Renal Dieases, G. Brotzu Hospital, Cagliari, Italy.
Davide ArgiolasKidney Transplant Unit, Department of Renal Dieases, G. Brotzu Hospital, Cagliari, Italy.
Sara LaiMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Elena CongedduKidney Transplant Unit, Department of Renal Dieases, G. Brotzu Hospital, Cagliari, Italy.
Paola RagatzuKidney Transplant Unit, Department of Renal Dieases, G. Brotzu Hospital, Cagliari, Italy.
Maurizio MelisRegional Transplant Center, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Elisabetta CartaKidney Transplant Unit, Department of Renal Dieases, G. Brotzu Hospital, Cagliari, Italy.
Maria Benigna MichittuKidney Transplant Unit, Department of Renal Dieases, G. Brotzu Hospital, Cagliari, Italy.
Donatella ValentiniMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Luisella CappaiMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Rita PorcellaMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Francesco AlbaMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Maria SerraMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Valentina LoiMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Roberta MaddiMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Sandro OrrùMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Giorgio La NasaBone Marrow Transplant Center, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Giovanni CaocciBone Marrow Transplant Center, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Roberto CusanoCenter for Advanced Studies, Research and Development (CRS4) Biomedical Sector, "Polaris" Technology Park, Pula, Cagliari, Italy.
Marcella ArrasBone Marrow Transplant Center, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
Mauro FrongiaComplex Structure of Urology, Kidney Transplantation and Robotic Surgery, G. Brotzu Hospital, Cagliari, Italy.
Antonello PaniComplex Structure of Nephrology and Dialysis, Department of Renal Diseases, G. Brotzu Hospital, Cagliari, Italy.
Carlo CarcassiMedical Genetics, R. Binaghi Hospital, ASSL Cagliari, ATS Sardegna, Italy.
ATS Sardegna (Italy) · ITAzienda Ospedaliera G. Brotzu · ITUniversity of Cagliari · ITCenter for Advanced Studies Research and Development in Sardinia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney transplantation is a life-saving treatment for patients with end-stage renal disease. However, despite progress in surgical techniques and patient management, immunological rejection continues to have a negative impact on graft function and overall survival. Incompatibility between donors and recipients for human leukocyte antigens (HLA) of the major histocompatibility complex (MHC) generates a series of complex cellular and humoral immune response mechanisms that are largely responsible for rejection and loss of graft function. Within this context, a growing amount of evidence shows that alloreactive natural killer (NK) cells play a critical role in the immune response mechanisms elicited by the allograft. Killer immunoglobulin-like receptors (KIRs) are prominent mediators of NK cell alloreactivity. METHODS AND

findingsA cohort of 174 first cadaveric kidney allograft recipients and their donors were selected from a total cohort of 657 transplanted patients for retrospective immunogenetic analyses. Patients with HLA Class II mismatches were excluded. HLA Class I allele frequencies were compared among patients with chronic rejection, patients with stable graft function and a group of 2388 healthy controls. Activating and inhibitory KIR gene frequencies, KIR haplotypes, KIR-HLA ligand matches/mismatches and combinations of recipient KIRs and donor HLA Class I ligands were compared among patients with and without chronic rejection and a group of 221 healthy controls. Patients transplanted from donors homozygous for HLA-C1 antigens had a significantly higher risk for chronic rejection than patients transplanted from donors homozygous or heterozygous for HLA-C2 antigens or with epitopes belonging to the HLA-Bw4 ligand group. The Kaplan-Meier curves obtained by dividing the patients into 3 groups according to the presence or absence of one or both of the combinations of recipient KIRs and donor HLA ligands (rKIR2DL1/dHLA-C2 and rKIR3DL1/dHLA-Bw4) showed a significantly higher cumulative incidence of chronic rejection in the group of patients completely lacking these functional units. These patients showed a progressively stronger decline in modification of diet in renal disease-estimated glomerular filtration rate.

conclusionsKIR genotyping should be performed at the time of enrolment of patients on the waiting list for organ transplantation. In our study, a significantly higher risk of chronic rejection after kidney transplantation was observed when recipient (r) and donor (d) pairs completely lacked the two functional rKIR-dHLA ligand combinations rKIR2DL1/dHLA-C2 and rKIR3DL1/dHLA-Bw4. This immunogenetic profile corresponds to low levels of NK cell inhibition. Therefore, patients with this high risk profile could benefit from immunosuppressive therapy aimed at reducing NK-cell cytotoxicity.

Indexed as

Kidney TransplantationAdultCadaverCase-Control StudiesFemaleGene ExpressionGlomerular Filtration RateGraft RejectionGraft SurvivalHistocompatibilityHLA-B AntigensHLA-C AntigensHumansKidney Failure, ChronicKiller Cells, NaturalLigandsHLA-B AntigensHLA-Bw4 antigenHLA-C AntigensKIR2DL1 protein, humanKIR3DL1 protein, humanLigandsReceptors, KIR2DL1Receptors, KIR3DL1

Identifiers

PMID28686681
PMCPMC5501603
OpenAlexW2729276298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.